If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Zyprexa ® (olanzapine)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Zyprexa Summary of Product Characteristics (SmPC)
Zyprexa coated tablets (olanzapine): Overdose
Information on signs and symptoms of olanzapine overdose and its management.
common symptoms in overdose (> 10 % incidence) include
tachycardia, agitation/aggressiveness, dysarthria, various
extrapyramidal symptoms, and reduced level of consciousness ranging
from sedation to coma.
medically significant sequelae of overdose include delirium,
convulsion, coma, possible neuroleptic malignant syndrome,
respiratory depression, aspiration, hypertension or hypotension,
cardiac arrhythmias (< 2 % of overdose cases) and cardiopulmonary
arrest. Fatal outcomes have been reported for acute overdoses as low
as 450 mg but survival has also been reported following acute
overdose of approximately 2 g of oral olanzapine.
is no specific antidote for olanzapine. Induction of emesis is not
recommended. Standard procedures for management of overdose may be
indicated (i.e. gastric lavage, administration of activated
charcoal). The concomitant administration of activated charcoal was
shown to reduce the oral bioavailability of olanzapine by 50 to 60 %.
treatment and monitoring of vital organ function should be instituted
according to clinical presentation, including treatment of
hypotension and circulatory collapse and support of respiratory
function. Do not use epinephrine, dopamine, or other sympathomimetic
agents with beta- agonist activity since beta stimulation may worsen
hypotension. Cardiovascular monitoring is necessary to detect
possible arrhythmias. Close medical supervision and monitoring should
continue until the patient recovers.
[Summary of Product Characteristics]. Utrecht, The Netherlands: Eli
Lilly Nederland B.V.
Date of Last Review:December 07, 2018
Are you satisfied with this content?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org